Recombinant Proteins Market Size & Share 2026-2035

Recombinant Proteins Market Size

The global recombinant proteins market was valued at USD 2.5 billion in 2025. The market is expected to grow from USD 2.6 billion in 2026 to USD 5.7 billion in 2035, at a CAGR of 9.3% during the forecast period, according to the latest report published by Global Market Insights Inc.

One of the primary drivers is the increasing demand for biopharmaceuticals and therapeutic proteins, which are essential in the treatment of various diseases such as cancer, diabetes, and autoimmune disorders. Additionally, the growing aging population coupled with rising prevalence of chronic diseases worldwide, is increasing the need for innovative treatment options, further propelling the demand for recombinant proteins. For instance, as per the U.S. Department of Health & Human Services, 85.6% of adults aged 65 and over have one or more chronic conditions, 56% have two or more, and 23.1% have three or more chronic diseases, in the U.S. Such rising burden of chronic diseases increases the demand for effective therapies, thereby boosting the market growth. Moreover, the expanding applications of recombinant proteins in research and diagnostics, are contributing to the market expansion.

Recombinant proteins are artificially created by combining DNA sequences from two different sources. This is typically done by inserting the desired DNA sequence into a host organism, such as bacteria, yeast, or mammalian cells, which then produce the protein encoded by that sequence. Recombinant proteins are widely used in research, diagnostics, and therapeutics, as they allow us to produce large quantities of specific proteins that may be difficult or impossible to isolate from natural sources.

Key players in the recombinant proteins market include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Bio‑Techne Corporation, and Bio‑Rad Laboratories. These companies play a central role in advancing the market through extensive recombinant protein portfolios, GMP‑grade manufacturing capabilities, customized protein expression services, and strong global distribution networks. Ongoing investments in protein engineering technologies, support for cell and gene therapy pipelines, expansion of diagnostic and research reagent offerings, and strategic collaborations with biopharmaceutical companies and research institutions continue to strengthen their competitive positioning.

Between 2022 and 2024, the market demonstrated steady and resilient growth, supported by rising biopharmaceutical R&D expenditure, increased adoption of biologics and biosimilars, and strong demand from cell and gene therapy, vaccine research, and diagnostics applications. During this period, the global market expanded from approximately USD 2.2 billion in 2022 to around USD 2.4 billion in 2024. Growth was further reinforced by increased outsourcing of protein production to specialized vendors, expanding use of high‑purity and GMP‑grade recombinant proteins, and broader access to advanced life‑sciences research infrastructure across both developed and emerging markets.

Recombinant Proteins Market Trends

• The increasing demand for biopharmaceuticals and therapeutic proteins is a significant driver of the market.
• Biopharmaceuticals, including therapeutic proteins, are vital in treating various diseases such as cancer, autoimmune disorders, and genetic diseases. Growing demand of biologics and antibody-based therapeutics, drives the demand for recombinant proteins.
• For instance, as per the National Institute of Health (NIH), in 2022, U.S. FDA approved fifteen biologics and monoclonal antibodies (mAbs) continued to account for majority of FDA approvals among them. Thus, growing demand for recombinant protein-based therapeutics, is expected to drive the market growth.
• Additionally, the rising prevalence of chronic diseases, the growing elderly population, and advancements in biotechnology are all contributing to the increased demand for biopharmaceuticals and therapeutic proteins, further driving the growth of the market.
• The rapid expansion of cell and gene therapy pipelines is significantly increasing demand for high‑purity and GMP‑grade recombinant proteins such as cytokines, growth factors, and enzymes used in upstream and downstream processes.
• Further, advancements in protein expression systems, including mammalian, insect, and yeast platforms, are enabling production of more complex and functionally active recombinant proteins, broadening their therapeutic and research applications.
• Growing adoption of AI‑enabled protein design and engineering technologies is accelerating novel protein discovery and optimization, thereby boosting demand for customized recombinant protein solutions.
• Also, increasing use of recombinant proteins in diagnostics, assay development, and biomarker identification is expanding market demand beyond therapeutics into clinical research and diagnostic manufacturing.
• Rising outsourcing of protein production and process development to specialized CROs and CDMOs by biopharmaceutical companies is further supporting market growth and accelerating time‑to‑market for biologics.

Recombinant Proteins Market Analysis

Based on products & services, the market is segmented into products and production services. The product segment is further segmented into cytokines & growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and other products. The products segment dominated the market is 2025 and accounted for USD 1.6 billion.

• High demand for products can be attributed to the wide range of applications of recombinant proteins across various industries, including pharmaceuticals, biotechnology, and research.
• Further, the increasing adoption of biopharmaceuticals, which rely heavily on recombinant proteins aids in market growth.
• Additionally, advancements in protein engineering technologies are enabling the production of recombinant protein products with enhanced properties, such as improved stability and bioactivity, further contributing to their market dominance.
• On the other hand, the production services segment is expanding steadily, driven by growing outsourcing by biopharmaceutical and biotechnology companies seeking to reduce capital investment, manage production complexity, and accelerate development timelines.

Based on application, the recombinant proteins market is segmented into drug discovery & development, research, diagnostics, and other applications. The drug discovery & development segment is further categorized into biologics, vaccines, and cell & gene therapies. The drug discovery & development segment dominated the market with 34.3% of market share in 2025.

• Recombinant proteins are essential in drug development processes, including target identification, validation, lead optimization, and preclinical and clinical trials. These proteins are used to study biological processes, evaluate drug candidates, and develop biologics for various therapeutic applications.
• The increasing demand for novel and effective therapies, coupled with advancements in biotechnology and protein engineering, is driving the growth of this segment.
• Additionally, the growing prevalence of chronic diseases and the increasing demand for personalized medicine have further fueled the demand for recombinant protein therapeutics, further augmenting the segmental growth.

Based on host-cells, the recombinant proteins market is categorized into mammalian systems, insect cells, yeast & fungi, bacterial cells, and other host-cells. The mammalian systems segment dominated the market and predicted to grow at CAGR of 9.2% over the forecast period.

• Mammalian cells hold a prominent position in the market, primarily due to their ability to produce complex proteins that closely mimic human proteins, making them crucial for therapeutic applications.
• Additionally, mammalian cells offer high protein yields and can produce large-scale batches, making them suitable for commercial production.
• Further, their widespread use in biopharmaceutical research and production has established mammalian cells as a cornerstone in the market.
• On the other hand, the bacterial cells segment holds a significant share of the market, driven by their cost‑effectiveness, rapid growth rates, and well‑established genetic manipulation techniques.

Based on end use, the recombinant proteins market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CRO's), and other end users. The pharmaceutical & biotechnology companies segment held highest market share in 2025 and is anticipated to reach USD 3 billion by 2035.

• Pharmaceutical and biotechnology companies hold a significant market share as end users in the market due to their pivotal role in drug development and research. These companies extensively utilize recombinant proteins in various stages of drug discovery, development, and production.
• Additionally, the increasing demand for biologics and personalized medicine further drives the adoption of recombinant proteins by pharmaceutical and biotechnology companies, solidifying their position as key players in this market.
• On the other hand, the contract research organizations (CROs) segment is witnessing steady growth, stimulated by increasing outsourcing of recombinant protein expression, characterization, and process development by pharmaceutical and biotechnology companies.

North America Recombinant Proteins Market

The North America market dominated the market with a market share of 48.4% in 2025.

• The region is home to a robust biotechnology and pharmaceutical industry, fostering innovation and research in protein therapeutics.
• Additionally, North America has a well-established healthcare infrastructure and a high prevalence of chronic diseases, driving the demand for recombinant proteins for therapeutic purposes.
• Moreover, the presence of leading market players and strong regulatory frameworks further contribute to the region's dominance.
• Lastly, increasing investments in research and development, along with a growing focus on personalized medicine in the region, drives the regional market growth.

The U.S. market was valued at USD 975.7 million and USD 1 billion in 2022 and 2023, respectively. The market size reached USD 1.1 billion in 2025, growing from USD 1 billion in 2024.

• The country's advanced biotechnology and pharmaceutical sectors, coupled with significant investments in R&D, drive innovation and product development in the field of recombinant proteins.
• Additionally, a robust ecosystem of biopharmaceutical companies, academic research institutions, and contract manufacturing organizations contributes to the market's growth.
• Further, the country's large and diverse patient population, coupled with a well-established healthcare infrastructure and insurance coverage, creates a significant market demand for these therapies, thereby accelerating market growth.

Europe Recombinant Proteins Market

Europe market accounted for USD 686.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe continues to show strong momentum due to robust biopharmaceutical R&D activity, well‑established biotechnology infrastructure, and high adoption of biologics and biosimilars across major markets such as Germany, the UK, France, and Switzerland.
• The region benefits from strong regulatory frameworks, advanced academic research ecosystems, and significant investment in cell and gene therapy development, driving sustained demand for research‑grade and GMP‑grade recombinant proteins.
• Additionally, growing focus on precision medicine, diagnostic innovation, and outsourcing of protein expression services supports continued expansion of the market across Europe.

Germany dominates the Europe market, with strong growth potential.

• Factors contributing to this growth include the country's robust biotechnology and pharmaceutical industries, strong research and development capabilities, and a favorable regulatory environment.
• Additionally, the increasing prevalence of chronic diseases and the rising demand for biopharmaceuticals are driving the growth of the market in Germany.

Asia Pacific Recombinant Proteins Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 9.8% during the analysis timeframe.

• Regional growth is supported by expanding biopharma R&D activity, increasing adoption of biologics and biosimilars, and growing demand for recombinant proteins in diagnostics and therapeutic development across China, India, Japan, and South Korea.
• The rise of cell and gene therapy pipelines, local CDMO ecosystem build‑out, and government‑backed life‑sciences initiatives is accelerating demand for both research‑grade and GMP‑grade recombinant proteins.

China market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• The country's expanding biopharmaceutical industry supported by favorable government policies is driving demand for recombinant proteins.
• Additionally, the rising prevalence of chronic diseases and an aging population in China are increasing the need for advanced biopharmaceuticals, including recombinant proteins, for therapeutic applications.
• Furthermore, the growing acceptance and adoption of biologics in the country's healthcare system, coupled with improving healthcare infrastructure and a growing emphasis on personalized medicine, are expected to further boost the growth of the market in China.

Latin America Recombinant Proteins Market

Brazil leads the Latin America market, exhibiting remarkable growth during the analysis period.

• The country's biopharmaceutical industry has rapidly expanded, stimulated by strong government support, a robust research infrastructure and a skilled workforce.
• Further, the country’s strategic focus on biotechnology and pharmaceuticals has led to advancements in recombinant protein production technologies, stimulating the market's growth.
• Additionally, a strong regulatory framework and emphasis on quality control further enhance its appeal as a destination for biopharmaceutical development and manufacturing.

Middle East and Africa Recombinant Proteins Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2025.

• Market expansion in Saudi Arabia is supported by increasing investments in biopharmaceutical infrastructure, government‑led initiatives under Vision 2030, and rising focus on biotechnology and life sciences development.
• The country is actively strengthening its research capabilities, biomanufacturing facilities, and clinical research ecosystem, which is creating growing demand for research‑grade and GMP‑grade recombinant proteins.

Recombinant Proteins Market Share

The market is characterized by a moderately concentrated yet highly competitive landscape, with a small group of leading companies generating a substantial share of global revenues. Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Bio‑Techne, GenScript Biotech, and Bio‑Rad Laboratories collectively account for approximately 60% of the global market, supported by their broad recombinant protein portfolios, strong protein engineering capabilities, and extensive global manufacturing and distribution networks. These companies maintain leadership across key application areas, including biopharmaceutical R&D, cell and gene therapy, diagnostics, and academic research, leveraging strengths in research‑grade and GMP‑grade protein offerings, customization services, and regulatory compliance.

Strategic expansion through product portfolio enhancement, investments in GMP manufacturing capacity, technology partnerships, and selective acquisitions continues to shape the competitive landscape. Leading players are actively strengthening capabilities in high‑purity cytokines, growth factors, immune checkpoint proteins, and custom protein expression services to support complex biologics and precision medicine workflows. Innovation remains centered on advanced protein engineering platforms, scalable bioprocessing technologies, and integration with cell and gene therapy ecosystems, driven by rising biopharmaceutical R&D spending, increasing outsourcing of protein production, and growing demand for high‑quality recombinant proteins across developed and emerging markets.

Recombinant Proteins Market Companies

Prominent players operating in the recombinant proteins industry include:

• Abnova
• ACROBiosystems Group
• Bio Rad Laboratories
• Bio Techne
• BPS Bioscience
• Creative BioMart
• GenScript Biotech
• Merck KGaA (MilliporeSigma)
• Miltenyi Biotec
• Proteintech Group
• ProteoGenix
• RayBiotech
• Sino Biological
• Thermo Fisher Scientific

 

• Thermo Fisher Scientific

Thermo Fisher Scientific holds a leading position in the market, supported by its extensive portfolio of research‑grade and GMP‑grade recombinant proteins, integrated life‑sciences tools, and end‑to‑end biopharma solutions. The company’s dominance is reinforced by strong global manufacturing capabilities, broad distribution networks, and continuous investment in bioprocessing and protein engineering technologies to support biologics, cell and gene therapy, and diagnostics development.

 

• Merck KGaA (MilliporeSigma)

Merck KGaA maintains a strong competitive position in the market through its high‑quality recombinant reagents, robust compliance with global regulatory standards, and deep integration across bioprocessing workflows. The company’s focus on scalable protein solutions, biosimilar development support, and sustained investment in innovation strengthens its leadership across pharmaceutical, biotechnology, and academic research segments.

 

• Bio‑Techne

Bio‑Techne plays a pivotal role in the market, driven by its premium cytokines, growth factors, and immune‑related protein portfolio widely used in translational research and advanced biologics development. Its emphasis on product quality, reproducibility, and custom protein services, combined with strong collaboration with biopharma and research institutions, positions Bio‑Techne as a key innovator supporting next‑generation therapeutic and diagnostic applications.

Recombinant Proteins Industry News

• In May 2024, Sanofi completed the acquisition of Inhibrx, adding the human recombinant protein candidate SAR447537 to its rare disease pipeline following shareholder approval and transaction close. This acquisition strengthened Sanofi’s position in rare disease biologics and expanded its recombinant protein‑based therapeutic pipeline.
• In April 2024, Sino Biological finalized the acquisition of Vancouver‑based SignalChem Biotech, gaining full ownership of its bioactive enzyme assets and proprietary production platforms. The transaction expanded Sino Biological’s recombinant protein and enzyme portfolio and enhanced its technical capabilities in research reagent and CRO services.
• In October 2023, Proteintech announced the launch of multi-rAb recombinant secondary antibodies, the newest generation of secondary antibodies. This helped the company to expand its product offerings.
• In February 2022, GenScript announced the opening of manufacturing facility in Singapore for highly automated protein and gene preparation services. The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms, and is designed to provide high quality, fast turnaround on products required for new vaccines and therapeutics development. This strategy helped the company strengthen its footprint in the Asia Pacific region.

The recombinant proteins market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Products & Services

• Products
  • Cytokines & growth factors
    • Interferons (IFNs)
    • Interleukins (ILs)
    • Other cytokines & growth factors
  • Antibodies
  • Immune checkpoint proteins
  • Virus antigens
  • Enzymes
    • Kinases
    • Metabolic enzymes
    • Other enzymes
  • Recombinant regulatory proteins
  • Hormones
  • Other products
• Production services

Market, By Application

• Drug discovery & development
  • Biologics
  • Vaccines
  • Cell & gene therapies
• Research
• Diagnostics
• Other applications

Market, By Host-cell

• Mammalian systems
• Insect cells
• Yeast & fungi
• Bacterial cells
• Other host-cells

Market, By End Use

• Pharmaceutical & biotechnology companies
• Academic & research institutes
• Contract research organizations (CRO's)
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE